Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Cambridge Nutritional Sciences EV-to-EBITDA?
Cambridge Nutritional SciencesLSE:CNSL EV-to-EBITDA is -0.22 as of Sep. 13, 2026. The stock has 4 warning signs investors should review. Among 515 Medical Devices & Instruments companies, Cambridge Nutritional Sciences ranks worse than 194174.56% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Cambridge Nutritional Sciences's enterprise value is £0.82 Mil.
Cambridge Nutritional Sciences's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was £-3.75 Mil. Therefore, Cambridge Nutritional Sciences's EV-to-EBITDA for today is -0.22.
The historical rank and industry rank for Cambridge Nutritional Sciences's EV-to-EBITDA or its related term are showing as below:
LSE:CNSL'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -69.33 Med: 0.93 Max: 372.07
Current: -0.22
During the past 13 years, the highest EV-to-EBITDA of Cambridge Nutritional Sciences was 372.07. The lowest was -69.33. And the median was 0.93.
LSE:CNSL's EV-to-EBITDA is ranked worse than 100% of 515
companies
in the Medical Devices & Instruments industry
Industry Median: 13.63
vs LSE:CNSL: -0.22
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Cambridge Nutritional Sciences's PE Ratio (TTM) for today is calculated as:
Cambridge Nutritional Sciences's share price for today is £0.014.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Cambridge Nutritional Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was £-0.024.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LSE:CNSL vs ISRG, BDX, RMD: EV-to-EBITDA Comparison
For the Medical Instruments & Supplies subindustry, Cambridge Nutritional Sciences's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cambridge Nutritional Sciences EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Cambridge Nutritional Sciences's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Cambridge Nutritional Sciences's EV-to-EBITDA falls into.
Cambridge Nutritional Sciences's current Enterprise Value is £0.82 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Cambridge Nutritional Sciences's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was £-3.75 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cambridge Nutritional Sciences (LSE:CNSL) has a EV-to-EBITDA of -0.22 as of Sep. 13, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Cambridge Nutritional Sciences. According to the industry distribution chart, Cambridge Nutritional Sciences ranks #999999 out of 515 companies in the Medical Devices & Instruments industry.
Is Cambridge Nutritional Sciences' EV-to-EBITDA too high?
Cambridge Nutritional Sciences' current EV-to-EBITDA is -0.22. Based on the distribution chart, Cambridge Nutritional Sciences ranks #999999 out of 515 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers.
How does Cambridge Nutritional Sciences' EV-to-EBITDA compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Cambridge Nutritional Sciences ranks #999999 out of 515 companies for EV-to-EBITDA. This places Cambridge Nutritional Sciences in the lower half of its industry. The industry median EV-to-EBITDA is 13.63. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 13.63, based on 515 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Cambridge Nutritional Sciences. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 13.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cambridge Nutritional Sciences's current EV-to-EBITDA is -0.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cambridge Nutritional Sciences stock overvalued right now?
Based on GuruFocus' analysis, Cambridge Nutritional Sciences (LSE:CNSL) is currently considered Possible Value Trap. The stock's GF Value™ is £0.02, compared to a current price of £0.01 — trading 30% below its estimated fair value. The current EV-to-EBITDA is -0.22. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Cambridge Nutritional Sciences (LSE:CNSL), the current EV-to-EBITDA is -0.22 as of Sep. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cambridge Nutritional Sciences PLC is a medical diagnostics company specializing in the development, manufacture, and distribution of food sensitivity test kits. Its product portfolio includes tests designed to detect immune reactions to various foods, helping healthcare professionals and patients identify dietary and lifestyle changes to improve long-term health and wellbeing. The company operates in the United Kingdom and serves the customer base across various countries through laboratories and healthcare providers. It generates revenue by selling diagnostic kits and providing clinical analysis services centered on food sensitivity and gut health. The group has two reportable segments: Health and Nutrition; and Corporate. The Health and Nutrition segment generates majority revenue.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:CNSL has been successfully added to your 
